American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 51-58 , July 2009

Tacrolimus Therapy in Adults With Steroid- and Cyclophosphamide-Resistant Nephrotic Syndrome and Normal or Mildly Reduced GFR

Received 6 October 2008 ,Accepted 28 February 2009.

References 

  1. Habashy D, Hodson EM, Craig JC. Interventions for steroid-resistant nephrotic syndrome: A systematic review. Pediatr Nephrol. 2003;18:906–912
  2. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445–453
  3. Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis (North America Nephrotic Syndrome Study Group). Kidney Int. 1999;56:2220–2226
  4. Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN. Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:351–356
  5. Kirpekar R, Yorgin PD, Tune BM, Kim MK, Sibley RK. Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. Am J Kidney Dis. 1992;39:1143–1152
  6. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43:1377–1384
  7. Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol. 2005;20:914–919
  8. Tarshich P, Tokin JN, Remstein J, et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10:590–593
  9. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353:1083–1091
  10. Budde K, Fritsche L, Neumayer HH. Differing proteinuria control with cyclosporine and tacrolimus. Lancet. 1997;349:330
  11. Schweda F, Liebl R, Riegger AJ, Kramer BK. Tacrolimus treatment for steroid-and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant. 1997;12:2433–2435
  12. Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004;19:3062–3067
  13. Segarra A, Vila J, Pou L, et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: A preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002;17:655–662
  14. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburai VP. Tacrolimus: A new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant. 2008;23:910–913
  15. Li X, Li H, Chen J, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant. 2008;23:1919–1925
  16. Li X, Lv R, He Q, et al. Early initiation of therapy tacrolimus or cyclophosphamide for idiopathic membranous nephropathy with severe proteinuria. J Nephrol. 2008;21:584–591
  17. Korbet SM, Schwartz MM, Lewis EJ, et al. Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. Am J Kidney Dis. 1994;23:773–783
  18. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7:56–63
  19. Chamienia A, Biedunkiewicz B, Krol E, Debska-Slizien A, Rutkowski B. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. Transplant Proc. 2006;38:81–85
  20. Falkiewicz K, Kaninska D, Nahaczewska W, et al. Renal function and tubular phosphate handling in long-term cyclosporine-and tacrolimus-based immunosuppression in kidney transplantation. Transplant Proc. 2006;38:119–122
  21. Sinha MD, Macleod R, Rigby E, Clark AGB. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant. 2006;21:1848–1854
  22. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14:931–938
  23. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus (A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation). Drugs. 1993;46:746–794
  24. Tang S, Tang AW, Tam MK, Ho YW. Use of tacrolimus in steroid-and cyclosporin-resistant minimal-change nephrotic syndrome. Am J Kidney Dis. 2003;75:199–204
  25. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:281–287

 Originally published online as doi: 10.1053/j.ajkd.2009.02.018 on May 1, 2009.

 X.L. and H.L. contributed equally to this work.

PII: S0272-6386(09)00520-4

doi: 10.1053/j.ajkd.2009.02.018

American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 51-58 , July 2009

Article Tools

* Image Usage & Resolution